COVID-19: Clinical aspects and therapeutics responses
Fecha
2020Autor
Khan, Suliman
Ali, Ashaq
Shi, Hongwei
Siddique, Rabeea
Shabana
Nabi, Ghulam
Hu, Junjie
Wang, Tiejun
Dong, Men
Zaman, Wajid
Han, Guang
Resumen
COVID-19 has created havoc in the world by causing thousands of demises in a short period of time. Up
till now, several attempts have been made for potential therapeutics against SARS-COV2. In this retrospective, single-center study, we extracted data from 122 COVID-19, RT-PCR confirmed patients. who
were treated with a new treatment strategy of lianhuaqingwen with Arbidol Hydrochloride. The patients
were either asymptomatic or had mild symptoms for COVID-19 disease. Of 122 patients 21 (17.21%)
patients developed severe conditions of COVID-19, while total 111 (90.9%) experienced mild symptoms
such as fever in 93 (76.22%) patients, cough in 23 (20.17%) and muscle pain were observed in total 8 (7%)
patients. Furthermore our newly applied drugs combination (Lianhuaqingwen and Arbidol
Hydrochloride) showed therapeutic effects in 5–7 days in patients with mild symptoms with 98% recovery rate. These results indicate that COVID-19 patients with mild symptoms can be treated with
Lianhuaqingwen and Arbidol Hydrochloride. However, extensive clinical investigations are required to
confirm the effectiveness of these drugs.
Palabras clave
COVID-19; Therapeutics; Mild symptoms; TCM; RecoveriesEnlace al recurso
https://doi.org/10.1016/j.jsps.2020.06.022Colecciones
Estadísticas Google Analytics
Comentarios
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.